exatecan mesylate
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Esophageal Cancer
Conditions
Esophageal Cancer, Gastric Cancer
Trial Timeline
Apr 1, 2001 → Sep 1, 2003
NCT ID
NCT00017212About exatecan mesylate
exatecan mesylate is a phase 2 stage product being developed by Daiichi Sankyo for Esophageal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00017212. Target conditions include Esophageal Cancer, Gastric Cancer.
What happened to similar drugs?
19 of 20 similar drugs in Esophageal Cancer were approved
Approved (19) Terminated (2) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00055952 | Phase 2 | Completed |
| NCT00055939 | Phase 2 | Completed |
| NCT00017212 | Phase 2 | Completed |
| NCT00005938 | Phase 2 | Completed |
| NCT00004866 | Phase 2 | Completed |
| NCT00004108 | Phase 2 | Completed |
| NCT00004060 | Phase 2 | Completed |
| NCT00004046 | Phase 2 | Completed |
| NCT00003951 | Phase 2 | Completed |
| NCT00004045 | Phase 2 | Completed |
| NCT00004047 | Phase 1 | Completed |
Competing Products
20 competing products in Esophageal Cancer